Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > CombiMatrix to Hold Conference Call to Discuss the Development of Array for Cancer Screening

Abstract:
CombiMatrix Corporation (Nasdaq:CBMX) will hold a conference call to discuss the development of its CombiMatrix Cancer Array (CCA) test for cancer screening. Dr. Amit Kumar, President and CEO of CombiMatrix will host this call and will make a short presentation, followed by Q&A. The CCA test is a cancer screening product with multi-billion dollar market potential. This product is in the R&D pipeline of CombiMatrix. This presentation will provide information about the product, its current development stage, its market potential, and other relevant information.

CombiMatrix to Hold Conference Call to Discuss the Development of Array for Cancer Screening

MUKILTEO, WA | Posted on October 4th, 2008

The presentation will start at 2 p.m. Pacific Time (5 p.m. Eastern) on Tuesday, October 7, 2008. To attend the conference call, dial the access number 1-800-868-1837 for domestic callers and 1-404-920-6604 for direct dial or international callers. Enter the Conference Code 85329577 followed by the # sign (85329577#). To view the slide presentation concurrently with the conference call click on the following link (or copy it to your URL): https://www.accuconference.com/customer/join/. Enter the Conference Code 85329577 and click "Join." The live call, including the slide presentation, may also be accessed on CombiMatrix's website at www.combimatrix.com, in the Investor/Events section, where playback will be available for 30 days beginning October 8, 2008.

####

About CombiMatrix Corporation
We are a diversified biotechnology business, through the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. We make the arrays using our patented in situ electrochemical synthesis process, which provides the ability to easily change array content to stay current with new developments and to meet the evolving needs of our customers. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. We have also developed the capabilities of producing arrays that utilize bacterial artificial chromosomes on our arrays, also enabling genetic analysis. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. ("CMDX"), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory.

Additional information about CombiMatrix Corporation is available at www.combimatrix.com or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory, and competitive developments, and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

For more information, please click here

Contacts:
CombiMatrix Corporation
Amit Kumar, Ph.D.
President & CEO
(425) 493-2000
Fax (425) 493-2010

Copyright © GlobeNewswire, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Bosch announces high-performance MEMS acceleration sensors for wearables June 27th, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

NMRC, University of Nottingham chooses the Quorum Q150 coater for its reliable and reproducible film thickness when coating samples with iridium June 27th, 2017

Picosunís ALD solutions enable novel high-speed memories June 27th, 2017

Nanomedicine

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Learning with light: New system allows optical ďdeep learningĒ: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017

Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017

Making vessels leaky on demand could aid drug delivery:Rice University scientists use magnets and nanoparticles to open, close gaps in blood vessels June 8th, 2017

Announcements

Bosch announces high-performance MEMS acceleration sensors for wearables June 27th, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

NMRC, University of Nottingham chooses the Quorum Q150 coater for its reliable and reproducible film thickness when coating samples with iridium June 27th, 2017

Picosunís ALD solutions enable novel high-speed memories June 27th, 2017

Events/Classes

Bosch announces high-performance MEMS acceleration sensors for wearables June 27th, 2017

Nanometrics to Participate in the 9th Annual CEO Investor Summit 2017: Accredited investor and publishing research analyst event held concurrently with SEMICON West and Intersolar 2017 in San Francisco June 27th, 2017

Letiís Autonomous-Vehicle System Embedded in Infineonís AURIX Platform: Letiís Low-Power, Multi-Sensor System that Transforms Distance Data into Clear Information About the Driving Environment Will Be Demonstrated at ITS Meeting in Strasbourg, June 19-22 June 20th, 2017

Nanomechanics to Host High-Speed Nanoindentation Webinar June 21: Leading nanomechanical technology provider will host educational webinar focused on high-speed nanoindentation and mechanical properties mapping June 12th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project